Sema4 provided revenue guidance for the year 2022. The company expects total revenue for fiscal year 2022 to be in the range of $215 million to $225 million, implying 23-29% growth excluding revenue associated with COVID-19, and Sema4 also expects to result over 350,000 tests in 2022 excluding COVID-19 tests.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.17 USD | -5.50% | +16.72% | +306.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+306.18% | 291M | |
-17.89% | 8.36B | |
+40.49% | 3.6B | |
-32.64% | 2.73B | |
-8.06% | 2.47B | |
-7.47% | 2.32B | |
-14.40% | 1.77B | |
-18.74% | 1.55B | |
-40.19% | 1.22B | |
+5.57% | 1.09B |
- Stock Market
- Equities
- WGS Stock
- News GeneDx Holdings Corp.
- Sema4 Provides Revenue Guidance for the Year 2022